Registration processes play a major role in allowing patients to access innovative treatment options within the shortest possible period of time. The more transparent and open the registration processes which allow a new drug to be presented at the service of patients, the closer these processes approach standards of developed countries, led by the European Union, the more effective health services will be in our country and the easier our patients' access to drugs will become.

The Registration Committee seeks to investigate, evaluate and propose solutions to the problems faced by the pharmaceutical industry and research-based pharmaceutical companies during registration and regarding other legal matters and to allow the formation of joint work platforms whereby pertinent public organizations and institutions can mutually discuss and share problems and solution proposals. It closely monitors legal and structural developments in the arena of registration in order to ensure that they are compliant with pertinent EU directives and international standards and shares the work it has conducted in this field with pertinent authorities.